From the Chairman/CEO
Welcome and thanks for visiting us at Cephalon.com. Two thousand and eight is off to a great start with the recent FDA approval and subsequent launch of TREANDA®, a novel therapy for chronic lymphocytic leukemia. Later this year, we will learn if the FDA will permit us to market TREANDA for Non-Hodgkins Lymphoma. We have a strong history of bringing first in class products to market that offer new or added benefits to patients and 2008 will offer additional opportunities for us to innovate.
Read more>>
We are Cephalon
A global biopharmaceutical company driven to expand the boundaries of science to improve human health. A company with first-in-class therapeutics, a rich oncology research pipeline and medications to treat central nervous system disorders, cancer, pain and addiction. A company dedicated to our patients, healthcare professionals, employees and communities.
2007 Annual Report
2007 was an important year for our stakeholders: patients, physicians, partners, employees and investors.>>
Lesley Russell, MB.Ch.B., M.R.C.P.
Executive Vice President
On the Cephalon commitment to oncology and TREANDA® >>
